Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Friday.

A number of other brokerages have also recently weighed in on MCRB. Chardan Capital restated a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Stock Up 7.4 %

Shares of Seres Therapeutics stock opened at $0.91 on Friday. The firm has a market cap of $154.59 million, a price-to-earnings ratio of -3.94 and a beta of 2.13. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $2.05. The company’s 50-day simple moving average is $0.82 and its 200-day simple moving average is $0.90.

Hedge Funds Weigh In On Seres Therapeutics

Large investors have recently modified their holdings of the stock. Virtu Financial LLC lifted its holdings in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 18,191 shares during the last quarter. Geode Capital Management LLC increased its position in Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 255,014 shares during the period. State Street Corp lifted its stake in Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 43,700 shares during the last quarter. Providence Wealth Advisors LLC boosted its holdings in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 22,250 shares during the period. Finally, FMR LLC grew its position in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after acquiring an additional 140,096 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.